Skip to content

Cryotherapy for prostate cancer

How cold destroys the tumor, whole-gland or focal, as first treatment or after radiotherapy.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 18, 2026
Book a consultation
Drawing of the pelvis seen from the side, with the bladder, the prostate, the rectum with an ultrasound probe inside, and two thin needles entering through the perineum into the prostate, with a bluish ice ball around the tumor
On this page

Quick answer

Cryotherapy destroys prostate cancer with cold, using thin needles that enter through the perineum, guided by ultrasound.1 It can treat the whole prostate or only the tumor area, as a first treatment or when cancer comes back after radiotherapy.3,4 The 2026 European guideline recommends offering it, for intermediate risk, only within clinical trials or registries, and accepts salvage after radiotherapy in highly selected patients.1 The American guideline includes cryoablation among the salvage options after radiotherapy.3

How cold destroys the tumor

Freezing kills cells in several ways at once. The cell loses water, proteins break down, ice crystals rupture the membrane and blood stops flowing in the small vessels of the area, so the tissue dies from lack of oxygen.1

How it is done

The European guideline describes the technique as follows:1

  • Needles through the perineum: thin freezing needles are placed in the prostate through the skin between the scrotum and the anus, guided by ultrasound in the rectum.
  • Protecting what is around it: temperature sensors sit next to the sphincter and the rectal wall, and a warmer inside the urethra protects the urinary channel.
  • Two cycles: the tissue is frozen and thawed twice, down to about minus 40 degrees Celsius in the middle of the gland and next to the nerves.
  • Current devices: third- and fourth-generation devices are the most used.

In whole-gland cryotherapy, the needles cover the entire prostate. In focal cryotherapy, only the tumor area, or one half of the prostate (hemi-ablation).4,9

As first treatment: the whole gland

Whole-gland cryotherapy was studied as an alternative to surgery and radiotherapy. The European guideline notes that there are no prospective comparative data on cancer control and that most studies are case series with short follow-up.1

  • Cochrane review: only two randomized trials, both against radiotherapy, with 307 men. Effects on death from cancer, quality of life and major complications were uncertain, with very low quality of evidence. There is no randomized trial against surgery or active surveillance.4
  • Canadian trial: 244 men randomized to cryotherapy or radiotherapy, all with hormone therapy beforehand. Progression at 3 years was 23.9% and 23.7%. Control biopsy showed cancer in 7.7% after cryotherapy and in 28.9% after radiotherapy.5
  • COLD registry: 1,198 men treated at several centers in the United States. At 5 years, 72.9% to 77.1% were free of PSA recurrence, depending on the definition used.6
  • American series at 5.6 years: 94 men, 75% with intermediate or high risk. At 5 years, 81% were free of PSA recurrence and 95% free of metastasis.10

The American guideline considers cryotherapy a non-standard option for intermediate risk, because there are no current trials comparing it with surgery or radiotherapy.2

Focal cryotherapy

In focal cryotherapy, only the tumor area is frozen. It is one form of focal therapy, with the same selection rules: a lesion visible on MRI, confirmed by biopsy, and a systematic biopsy to check the rest of the prostate.1,8

  • English registry: 122 men with intermediate (71.3%) or high (28.7%) risk, most with tumors in the front of the prostate. At 3 years, 90.5% had not needed whole-gland or systemic treatment.8
  • Hemi-ablation, 5 years: 160 men, 82% with intermediate or high risk. At 5 years, 85% were free of treatment failure, 89% free of clinically significant cancer and 62% free of PSA recurrence by the criterion used.9
  • COLD registry: 1,160 men. At 3 years, 75.7% were free of PSA recurrence.7

In a group in which 76% of tumors were ISUP 1, focal cryotherapy showed no advantage in metastasis or survival compared with active surveillance.1

Side effects

Side effects depend on how much of the prostate is frozen. The larger the area, the more erections are affected.1

StudyContinenceErectionsRectourethral fistula
Whole gland, COLD registry (1,198 men)95.2% without leakage; 2.9% used pads25.2% had intercourse; 8.8% without medication or device0.4%
Whole gland, American series (94 men)96%11%None
Focal, COLD registry (1,160 men)98.4% pad-free58.1% with spontaneous erections0.1%
Focal, English registry (122 men)No one used pads16.1% without erections sufficient for penetrationNot reported
Hemi-ablation (160 men)97%73%None

Sources: whole-gland COLD registry,6 American series,10 focal COLD registry,7 English registry8 and hemi-ablation.9 In the focal COLD registry, 1.1% had urinary retention lasting more than 30 days.7

Salvage after radiotherapy

When PSA rises after radiotherapy, some men have cancer that has come back only inside the prostate. In these cases, local salvage treatment may be considered. The page PSA rising after radiotherapy explains the whole path.

What the guidelines say:

  • The American guideline asks for a prostate biopsy before any local salvage and, with recurrence confirmed, recommends offering prostatectomy, cryoablation, HIFU or re-irradiation, through shared decision-making (moderate recommendation).3
  • The European guideline accepts HIFU or cryoablation in highly selected patients with biopsy-proven recurrence, within a clinical trial or a well-designed prospective cohort study (weak recommendation).1

Results:

  • Review of 32 studies (5,513 patients): 67.5% were free of PSA recurrence at 2 years and 50.3% at 5 years, with low certainty of evidence. Recurrence was lower with PSA below 5 ng/mL, more than 70 months since radiotherapy, whole-gland treatment and added hormone therapy.1
  • COLD registry: 279 men. At 5 years, 54.5% to 58.9% were free of PSA recurrence, depending on the definition used.11
  • Two centers, 10 years: 268 men followed for a median of 10.3 years. At 10 years, 81% had not died of prostate cancer and 69% had not needed hormone therapy.12
  • 2026 review (4,525 patients): compared local salvage treatments given without hormone therapy. Severe complications were 2% with cryotherapy, 5% with high-dose-rate brachytherapy and with HIFU, 4% with stereotactic radiotherapy, 13% with prostatectomy and 14% with low-dose-rate brachytherapy. The studies were not randomized.13

Side effects of salvage: according to the European guideline, urine leakage in about 8.5%, sloughing or narrowing of the urethra in 3% and fistula in 1%.1 In the COLD registry, 4.4% used pads, 1.2% had a fistula and 3.2% needed a transurethral procedure to remove dead tissue that had come loose in the urethra.11

Follow-up

After whole-gland cryotherapy, some prostate tissue usually remains, and PSA often does not fall to zero. In the COLD registry, 72.5% had a PSA of 0.2 ng/mL or more at 5 years.6 In the American series, men who did not reach a PSA below 0.2 ng/mL within 6 months had a higher risk of recurrence.10

After focal cryotherapy, follow-up is the same as for focal therapy: PSA every 3 months in the first year, MRI at 6 and 18 months and a biopsy between 6 and 12 months, according to an international consensus.14

Guideline summary

SituationEuropean guideline (2026)American guideline
Intermediate risk, first treatmentWhole gland or focal only within studies or registries (strong)Non-standard option; focal therapy remains investigational
High riskDo not offer (strong)Do not recommend outside a clinical trial
Locally advancedDo not offer (strong)Do not recommend outside a clinical trial
Recurrence only in the prostate after radiotherapyHighly selected patients, with biopsy, in a study or prospective cohort (weak)One of the salvage options, with biopsy first (moderate)

Sources: European guideline,1 American guideline on localized cancer2 and American salvage guideline.3

Second opinion

If you have been offered cryotherapy, as a first treatment or after radiotherapy, and want to understand the other options, a second opinion can be done entirely online, in English, with your test results sent in advance. The pages surgery or radiotherapy and active surveillance help with the comparison.

Send your case

If you are considering cryotherapy, or have had it and have questions, and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is cryotherapy for prostate cancer?

It destroys cancer with cold. Thin needles enter through the perineum, guided by ultrasound, and freeze the tissue in two freeze-thaw cycles, down to about minus 40 degrees Celsius.1 It can treat the whole prostate or only the tumor area (focal cryotherapy).4

Is cryotherapy recommended as a first treatment?

With restrictions. The European guideline recommends offering cryotherapy, whole-gland or focal, for intermediate risk only within clinical trials or registries, and not offering it for high-risk or locally advanced cancer.1 The American guideline considers cryotherapy a non-standard option for intermediate risk.2

Is cryotherapy as effective as radiotherapy or surgery?

This is not known with confidence. The Cochrane review found only two randomized trials, against radiotherapy, with 307 men, and the quality of evidence was very low. There is no randomized trial against surgery or active surveillance.4 In the larger trial, progression at 3 years was 23.9% with cryotherapy and 23.7% with radiotherapy.5

Does cryotherapy cause impotence or incontinence?

With whole-gland treatment, loss of erections is common. In a series of 94 men, 96% were continent and 11% kept their erections.10 Focal cryotherapy preserves erections more often. In a series of 160 men treated in half of the prostate, 97% were continent and 73% kept their erections at 5 years.9

Can cryotherapy be used when cancer comes back after radiotherapy?

It can, in selected cases, with the recurrence confirmed by biopsy. The American guideline includes cryoablation among the salvage options, alongside surgery, HIFU and re-irradiation.3 In a review of 32 studies cited by the European guideline, about 50% were free of PSA recurrence at 5 years.1

What are the risks of salvage cryotherapy?

They are higher than with first treatment. According to the European guideline, urine leakage occurs in about 8.5%, tissue sloughing or narrowing of the urethra in 3% and a fistula between the rectum and urethra in 1%.1 In a registry of 279 men, 4.4% used pads and 1.2% had a fistula.11

What is follow-up like after cryotherapy?

With PSA and, when needed, MRI and biopsy. After whole-gland cryotherapy, not reaching a PSA below 0.2 ng/mL within 6 months was a sign of higher risk of recurrence.10 After focal cryotherapy, a consensus proposes MRI at 6 and 18 months and a biopsy between 6 and 12 months.14

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  2. Eastham JA, Barocas DA, Chu CE, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026). J Urol. 2026;216(1):2-11. PubMed
  3. Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024;211(4):526-532. PubMed
  4. Jung JH, Risk MC, Goldfarb R, et al. Primary cryotherapy for localised or locally advanced prostate cancer. Cochrane Database Syst Rev. 2018;5(5):CD005010. PubMed
  5. Donnelly BJ, Saliken JC, Brasher PM, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer. 2010;116(2):323-330. PubMed
  6. Jones JS, Rewcastle JC, Donnelly BJ, et al. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180(2):554-558. PubMed
  7. Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012;109(11):1648-1654. PubMed
  8. Shah TT, Peters M, Eldred-Evans D, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol. 2019;76(1):98-105. PubMed
  9. Oishi M, Gill IS, Tafuri A, et al. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years. J Urol. 2019;202(6):1188-1198. PubMed
  10. Oishi M, Gill IS, Ashrafi AN, et al. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up. Eur Urol. 2019;75(2):208-214. PubMed
  11. Pisters LL, Rewcastle JC, Donnelly BJ, et al. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180(2):559-563. PubMed
  12. Chin JL, Lavi A, Metcalfe MJ, et al. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. J Urol. 2021;206(3):646-654. PubMed
  13. Miszczyk M, Mastroleo F, Kujawska A, et al. Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis. JAMA Oncol. 2026;12(6):637-647. PubMed
  14. Lebastchi AH, George AK, Polascik TJ, et al. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. Eur Urol. 2020;78(3):371-378. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides